恩格列净与达格列净在2型糖尿病合并MASLD患者中的肝脏有效性比较
结果显示,恩格列净相比达格列净在FLI定义的MASLD逆转上 marginally 更高(HR 1.06;95%CI 1.00,1.11),而失代偿肝脏事件风险相当(HR 0.99;95%CI 0.94,1.03)。
要点
- 恩格列净与达格列净在失代偿肝脏事件风险上无显著差异。
- 恩格列净与FLI定义的MASLD逆转可能性 marginally 更高相关。
- 剂量分层分析结果与主要分析一致。
核心结论
- 在MASLD患者中,恩格列净与达格列净在失代偿肝脏事件风险上无显著差异。
研究设计与样本
- 基于韩国全国理赔数据的新用户队列研究,纳入2型糖尿病且FLI≥60的MASLD成人,比较恩格列净与达格列净。
- 共265,098名新用户,经1:1倾向评分匹配后形成101,487对,平均年龄54.3岁,男性占71.3%。
主要发现
- 恩格列净相比达格列净的FLI定义MASLD逆转HR为1.06(95%CI 1.00,1.11)。
- 失代偿肝脏事件(腹水、静脉曲张出血、肝衰竭、肝移植)HR为0.99(95%CI 0.94,1.03)。
- 剂量分层分析:低剂量FLI逆转HR 1.19(95%CI 0.77,1.83),高剂量HR 1.14(95%CI 1.01,1.28)。
- 剂量分层分析:低剂量失代偿肝脏事件HR 0.95(95%CI 0.74,1.23),高剂量HR 1.04(95%CI 0.93,1.15)。
临床怎么用
- 对于2型糖尿病合并MASLD患者,恩格列净与达格列净在失代偿肝脏事件预防上效果相当。
- 恩格列净在改善FLI定义的MASLD逆转方面可能略有优势,但差异幅度小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: While both empagliflozin and dapagliflozin are known to improve hepatic steatosis and liver enzyme levels, robust phase 3 trial evidence for improving steatohepatitis and fibrosis is currently exclusive to dapagliflozin. Therefore, a head-to-head comparison between two agents is warranted, to compare the hepatic outcomes between empagliflozin and dapagliflozin in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: Using nationwide Korean claims data, we constructed a new-user cohort of adults with MASLD, defined as having type 2 diabetes and a fatty liver index (FLI) ≥60, who initiated empagliflozin or dapagliflozin between May 2016 and December 2023. Outcomes of interest were FLI-defined MASLD regression (achieving FLI <30) and decompensated hepatic events (ascites, variceal bleeding, hepatic failure, liver transplantation). After 1:1 propensity score matching, HRs and 95% CIs were estimated using Cox models. RESULTS: Among 265,098 new users of empagliflozin and dapagliflozin, 101,487 pairs were 1:1 propensity score-matched (mean age 54.3 years; male 71.3%). Compared with dapagliflozin, empagliflozin was associated with a marginally higher likelihood of FLI-defined MASLD regression (HR 1.06; 95% CI 1.00, 1.11). The risk of decompensated hepatic events was comparable (HR 0.99; 95% CI 0.94, 1.03). Dose-stratified analyses yielded consistent findings in both FLI-defined MASLD regression (low-dose: HR 1.19; 95% CI 0.77, 1.83; high-dose: 1.14; 1.01, 1.28) and decompensated hepatic events (low-dose: 0.95; 0.74, 1.23; high-dose: 1.04; 0.93, 1.15). CONCLUSIONS/INTERPRETATION: Among individuals with MASLD, no significant differences were observed between empagliflozin and dapagliflozin in the risk of decompensated hepatic events.
引用
- Kim S, Ko HY, Hong B, et al. Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Diabetologia. 2026. PMID: 42814151. doi:10.1007/s00125-026-06870-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。